Lonapegsomatropin
- Generic Name
- Lonapegsomatropin
- Brand Names
- Skytrofa, Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1934255-39-6
- Unique Ingredient Identifier
- OP35X9610Y
- Background
Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to insufficient growth hormone secretion. Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administere...
- Indication
In the US, lonepegsomatropin is indicated in the treatment of growth failure due to inadequate growth hormone secretion in patients one year and older who weigh at least 11.5 kg. In Europe, lonepegsomatropin is indicated to treat growth failure in children and adolescents aged from three years up to 18 years due to insufficient endogenous growth hormone secr...
- Associated Conditions
- Growth Failure
- Associated Therapies
- -
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 48
- Registration Number
- NCT05690386
- Locations
- 🇺🇸
Ascendis Pharma Investigational Site, Seattle, Washington, United States
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 233
- Registration Number
- NCT05171855
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, Leeds, United Kingdom
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 264
- Registration Number
- NCT04615273
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.